Eribulin Mesylate + Capecitabine
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Sep 20, 2006 → Dec 11, 2017
NCT ID
NCT00337103About Eribulin Mesylate + Capecitabine
Eribulin Mesylate + Capecitabine is a phase 3 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00337103. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01439282 | Phase 2 | Completed |
| NCT01323530 | Phase 1/2 | Completed |
| NCT00337103 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer